エピソード
-
In this exciting episode of Venture Vitals, Tomas and Evgeny sit down with Marco and Jonas, the CEO and COO of ROOK, to explore the intricacies of launching and growing a healthtech startup in the US. Tune in to hear:
• Marco and Jonas share their personal journeys into health tech.
• The inspiration behind starting ROOK and the innovative idea driving their startup.
• Insights on team building and the importance of co-founders in a startup’s success.
• The unique challenges of establishing a startup in the US as international founders.
• Their strategies for overcoming current challenges and their vision to achieve unicorn status.
• The EXIT plan and the roadmap ahead for ROOK.
• Key challenges and essential collaborations in the digital health sector.
• FDA regulations and their impact on ROOK’s solutions.
Join us for an in-depth conversation about digital health ventures and the entrepreneurial journey of ROOK. Don’t miss it!
Marco Benitez - CEO, ROOK
Tae Kwon Do champion turned biomedical engineer turned CEO, Marco’s experiences and passion have given him a deep knowledge of the fitness, sports, and pharmaceutical industries. He values discipline, perseverance, and persistence, and strives to give to others what his fitness and coaches gave to him—an opportunity for a greater life.
Jonas Dücker - COO, ROOK
With an MBA as well as degrees in both international business and entrepreneurship, Jonas is fascinated by projects rooted in creating change. His years of experience in scaling fitness-tech startups and in social impact companies provide him with the organization, dedication, and out-of-the-box thinking that power innovation.
What is ROOK?
ROOK's API empowers companies with more meaningful health data. Easily process and embed data from hundreds of wearables with one single integration and gain access to deeper understanding and more actionable insights to drive innovation. More info via https://www.tryrook.io/ -
In this compelling episode of Venture Vitals, Tomas and Evgeny sit down with Allan Gobbs, Managing Partner at NY-based Life Sciences venture firm ATEM Capital, to uncover the secrets of health tech investment success. Join us as Allan shares his extraordinary journey from managing a $760M partnership to celebrating multiple NASDAQ listings and high-profile exits.
• Allan’s path to becoming a venture capital virtuoso in digital health.
• Essential advice for aspiring venture capitalists aiming to break into the industry.
• Key components of a successful startup pitch to secure investment from ATEM Capital.
• Insights into Allan’s preferred investment stages and strategies for startups.
• Distinctions between investing in digital health versus other tech sectors.
• Allan’s most triumphant investment stories and the journeys to successful exits.
• Predictions on the next big revolution in digital health.
• Crucial advice for health tech founders and investors.
Allan Gobbs
Allan Gobbs is a Managing Partner at NY-based Life Sciences venture firm ATEM Capital. Prior to ATEM he managed a $760M partnership with Domain Associates. Over the last few years Allan had 5 of his portfolio companies listed on NASDAQ, notably Atea Pharmaceuticals, which yielded a 30x return at IPO, Marinus and Syndax. Four of his portfolio companies have been sold, including Tobira Therapeutics, which was acquired by Allergan at a record 19x premium. Before ATEM Capital, Gobbs was a VP at Barclays Capital and Dresdner Kleinwort, where he advised on M&A and capital market transactions exceeding $20B. Allan is a member of the Forbes Business Council, the Private Directors Association, and the Review Committee of the National Cancer Institute at NIH. More info via https://atemcap.com/ -
エピソードを見逃しましたか？
